|
gptkbp:instanceOf
|
inhalational anesthetic
halogenated ether
|
|
gptkbp:aroma
|
pungent, ethereal
|
|
gptkbp:ATCCode
|
N01AB06
|
|
gptkbp:blood/gas_partition_coefficient
|
1.4
|
|
gptkbp:boilingPoint
|
48.5 °C
|
|
gptkbp:brand
|
Forane
IsoFlo
|
|
gptkbp:CASNumber
|
26675-46-7
|
|
gptkbp:category
|
Ether
chloroarene
general anesthetic
halogenated compound
organofluoride
|
|
gptkbp:chemicalFormula
|
C3H2ClF5O
|
|
gptkbp:color
|
colorless
|
|
gptkbp:contraindication
|
history of malignant hyperthermia
hypersensitivity to isoflurane
|
|
gptkbp:countryOfOrigin
|
gptkb:Australia
gptkb:Canada
gptkb:India
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:density
|
1.496 g/cm³
|
|
gptkbp:discoveredBy
|
Ross C. Terrell
|
|
gptkbp:eliminationHalfLife
|
very short
|
|
gptkbp:flammability
|
non-flammable
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Isoflurane
|
|
gptkbp:introduced
|
1980
|
|
gptkbp:IUPACName
|
1-chloro-2,2,2-trifluoroethyl difluoromethyl ether
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:MAC_(minimum_alveolar_concentration)_in_adults
|
1.15%
|
|
gptkbp:mechanismOfAction
|
inhibits NMDA receptor activity
potentiates GABA_A receptor activity
|
|
gptkbp:meltingPoint
|
-140 °C
|
|
gptkbp:metabolism
|
minimal (mainly exhaled unchanged)
|
|
gptkbp:molecularWeight
|
184.5 g/mol
|
|
gptkbp:routeOfAdministration
|
inhalation
|
|
gptkbp:sideEffect
|
nausea
malignant hyperthermia
hypotension
respiratory depression
shivering
|
|
gptkbp:solubility
|
very low
|
|
gptkbp:storage
|
store at room temperature
|
|
gptkbp:used_in_veterinary_medicine
|
yes
|
|
gptkbp:usedFor
|
general anesthesia
|
|
gptkbp:vapor_pressure_(at_20°C)
|
238 mmHg
|
|
gptkbp:vaporizer_required
|
yes
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Carestation_600_Series
gptkb:Anesthetic
|
|
gptkbp:bfsLayer
|
7
|